Navigation Links
Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial
Date:9/23/2010

Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy... -- ABBOTT PARK, Ill., Sept. 23 /PRNewswire-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Health Care & Hospitals, Medical Equipment, Medical Pharmaceuticals, Clinical Trials & Medical Discoveries Click to view news release full screen  

Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial

   

-- Two-Year Results from Independent 'All-Comers' Study of 1,800 Real-World Patients Compared XIENCE V to the Newer-Generation TAXUS® Liberte®-- Data Show that the Differences in the Two Stents Increase at Two Years-- In the Study, Patients Receiving XIENCE V Had a 77 Percent Lower Rate of Stent Thrombosis (Blood Clot) than TAXUS Liberte at Two Years

ABBOTT PARK, Ill., Sept. 23 /PRNewswire-FirstCall/ -- Late-breaking data were presented today from the investigator-initiated COMPARE trial of 1,800 real-world patients involving Abbott's (NYSE: ABT) market-leading XIENCE V® Everolimus Eluting Coronary Stent System and the TAXUS® Liberte® Paclitaxel-Eluting Coronary Stent System (TAXUS). The results from COMPARE at two years were presented by Peter Smits, M.D., of Maasstad Ziekenhuis, Rotterdam, the Netherlands, during the Cardiovascular Research Foundation's 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) conference in Washington, D.C.

For the endpoint of major adverse cardiac events (MACE) at two years, which is a composite of all death, non-fatal heart attack (myocardial infarction or MI) and target vessel revascularization (TVR), XIENCE V showed a 34 percent lower incidence of MACE compared to TAXUS (9.0 percent for XIENCE V vs. 13.7 percent for TAXUS, p-value=0.0016). The composite secondary endpoint of cardiac death, non-fatal MI and target lesion revascularization (TLR) resulted in a 35 percent lower incidence for XIENCE V compared to TAXUS (7.4 percent for XIENCE V vs. 11.4 percent for TAXUS, p-value=0.0038).

In addition, XIENCE V demonstrated a 77 percent lower rate of stent thrombosis, defined as definite or probable according to ARC (0.9 percent for XIENCE V vs. 3.9 percent for TAXUS, p-value=<0.0001); a 60 percent lower rate of TVR (3.1 percent for XIENCE V vs. 7.7 percent for TAXUS, p-value=<0.0001); a 56 percent lower rate of TLR (2.6 percent XIENCE V vs. 5.9 percent TAXUS, p-value=0.0005); and a 49 percent lower rate of non-fatal MI (3.9 percent XIENCE V for vs. 7.6 percent for TAXUS, p-value=0.0009).

The stent thrombosis rate for XIENCE V between one and two years increased from 0.7 percent at one year to 0.9 percent at two years, while the TAXUS arm increased from 2.6 percent at one year to 3.9 percent at two years. At two years, 88.6 percent of XIENCE V patients and 84.8 percent of TAXUS patients had discontinued dual-antiplatelet therapy.

"The COMPARE results show that the gap in stent thrombosis rates between XIENCE V and TAXUS Liberte widened from 1.9 percent at one year to 3.0 percent at two years," said Charles A. Simonton, M.D., FACC, FSCAI, divisional vice president, Medical Affairs, and chief medical officer, Abbott Vascular. "The COMPARE investigators have provided some of the first major insights into the comparative long-term differences in stent thrombosis rates between one and two years for different stent platforms."

"The two-year results presented today for the COMPARE trial and for the SPIRIT IV trial demonstrate impressive outcomes for XIENCE V compared to TAXUS Liberte and TAXUS Express, respectively," said Robert Hance, senior vice president, vascular, Abbott. "Both of these trials show the differences in the performance of these drug eluting stents and add to the ever-growing body of safety and efficacy data for XIENCE V – reinforcing why XIENCE V continues to be the market-leading drug eluting stent."

About The COMPARE StudyThe COMPARE study is a physician-initiated "all-comers" trial sponsored by Maasstad Ziekenhuis of Rotterdam, the Netherlands. The study, designed to reflect real-world, everyday clinical practice, enrolled 1,800 patients in a single- center, prospective randomized (1:1) comparison of safety and efficacy of the XIENCE V™ Everolimus Eluting Stent System to the TAXUS® Liberte® Paclitaxel-Eluting Coronary Stent System.  The COMPARE trial was supported in part by an Abbott grant.  All aspects of the trial were designed and conducted independent of Abbott.

About XIENCE VAbbott's market-leading XIENCE V drug eluting stent is marketed in the United States, Europe, Japan and other international markets.

Everolimus, developed by Novartis Pharma AG, is a proliferation signal inhibitor, or mTOR inhibitor, licensed to Abbott by Novartis for use on its drug eluting stents. Everolimus has been shown to inhibit in-stent neointimal growth in the coronary vessels following stent implantation, due to its anti-proliferative properties.

XIENCE V is indicated for improving coronary luminal diameter in patients with symptomatic heart disease due to de novo native coronary artery lesions (lesions less than or equal to 28 mm) with reference vessel diameters of 2.5 mm to 4.25 mm. Additional information about XIENCE V, including important safety information, is available online at www.xiencev.com or www.abbottvascular.com/en_US/content/document/eIFU_XienceV.pdf.

About Abbott VascularAbbott Vascular is a global leader in cardiac and vascular care with market-leading products and an industry-leading pipeline. Abbott Vascular offers a comprehensive cardiac and vascular devices portfolio, including products for coronary artery disease, vessel closure, endovascular disease, and structural heart disease.

About Abbott Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs nearly 90,000 people and markets its products in more than 130 countries.  

Abbott's news releases and other information are available on the company's Web site at www.abbott.com.


'/>"/>

SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Abbott to Present Data on Market-Leading XIENCE V® and Promising Vascular Pipeline at TCT 2010
2. New Data Reinforces Safety Profile of Abbotts Market-Leading XIENCE V(R) Drug Eluting Stent
3. Abbotts XIENCE V(R) Demonstrates Significantly Lower Rates of MACE and Stent Thrombosis Compared to TAXUS(R) Liberte in Investigator-Initiated COMPARE Trial
4. Abbotts XIENCE V(R) Superior to TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV Trial
5. Abbotts XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial
6. Abbotts Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
7. Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
8. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
9. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
10. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
11. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Feb. 12, 2016 /PRNewswire/ - Demers Ambulances announces its first delivery ... Okaloosa County Emergency Medical Services (EMS) ... and one LT2 van. Quality Emergency Vehicles in ... for the sale.  This is the latest in Demers, ongoing ... Vice President at Demers. --> Benoit LaFortune , ...
(Date:2/12/2016)... 12. Februar 2016  Sequent Medical, Inc. gab ... Patienten für eine Studie zur Sicherheit und Wirksamkeit ... für die Behandlung von rupturierten intrakraniellen Aneurysmen begonnen ... der Neuroradiologie an der Universitätsklinik Bicètre in ... CLARYS-Studie hat den ersten Patienten aufgenommen. ...
(Date:2/12/2016)... SEOUL, South Korea , Feb. 12, 2016 ... today announced they will form a partnership to ... medicine in cancer. The goal of the collaboration ... with Macrogen,s high-throughput Next Generation Sequencing capabilities toward ... Laboratory Improvement Amendments (CLIA) of 1988 by the ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... AssureVest Insurance Group, a locally owned insurance ... drive that will raise funds earmarked to purchase computers and software for Mrs. Harrison’s ... “My school is in a low-income area and has more than 60 2nd and ...
(Date:2/12/2016)... ... ... Erlanger Agency has announced a new partnership in its ongoing community involvement ... the fight against breast cancer, fundraising for a local woman named Carmen, who is ... is a loving single mother of two boys who also serves as caregiver for ...
(Date:2/12/2016)... MIAMI, FLA (PRWEB) , ... February 12, 2016 , ... ... free dental implants to their Miami dental office. Beginning in January, Miami Dental ... traditional titanium. Miami Dental Specialists are the first office to be chosen by the ...
(Date:2/12/2016)... NY (PRWEB) , ... February 12, 2016 , ... ... of “Revolutionizing Cancer Care.” , The print component of “Revolutionizing Cancer ... Dallas, Pittsburgh/Cleveland, New York, Washington DC/Baltimore, and Seattle, with a circulation of approximately ...
(Date:2/12/2016)... ... 2016 , ... Homeowners now have a next generation tool ... leading brand of building products, has improved upon its industry-best array of home ... of the ColorView® Exterior Style and Color Selector. Created expressly for the iPad®, ...
Breaking Medicine News(10 mins):